Methods for predicting time-to-delivery in pregnant women

Abstract

The present disclosure relates to methods for predicting time-to-delivery in pregnant women. The methods include predicting that a pregnant woman will deliver within a predetermined time frame if PAMG-1 is determined to be present at a level above a predetermined detection threshold in a vaginal fluid sample obtained from the pregnant woman. Also provided are methods for determining a patient's risk of preterm labor and/or spontaneous rupture of the chorioamniotic membrane.

1 .- 2 . (canceled) 
     
     
         3 . A method for determining a pregnant woman's risk of spontaneous rupture of the chorioamniotic membranes, the method comprising:
 (a) contacting a vaginal fluid sample obtained from a pregnant woman with at least two PAMG-1-specific monoclonal antibodies, wherein at least one of the antibodies binds to PAMG-1 when present in the sample to form a PAMG-1/monoclonal antibody complex;   (b) detecting the presence of the PAMG-1/monoclonal antibody complex in the sample only when the concentration of PAMG-1 in the sample exceeds a predefined detection threshold wherein the predetermined detection threshold level of PAMG-1 is 4 ng/ml; and   (c) determining that the pregnant woman is at risk of spontaneous rupture of the chorioamniotic membranes if PAMG-1 is detected; or   (d) determining that the pregnant woman is not at risk of spontaneous rupture of the chorioamniotic membranes if PAMG-1 is not detected.   
     
     
         4 . The method of  claim 3 , further comprising determining that the fetal membranes of the pregnant woman are intact. 
     
     
         5 . The method of  claim 3 , comprising selecting the pregnant woman for analysis by the method only if the pregnant woman presents with one or more of the following:
 (i) signs, symptoms or complaints suggestive of preterm labor;   (ii) a gestational age between 20 weeks and 36 weeks, 6 days;   (iii) a cervical length of 25 mm or more; and   (iv) a cervical dilatation of 3 cm or less.   
     
     
         6 . The method of  claim 5 , comprising selecting the pregnant woman for analysis by the method only if the pregnant woman presents with two or more of (i), (ii), (iii), and (iv). 
     
     
         7 . The method of  claim 6 , comprising selecting the pregnant woman for analysis by the method only if the pregnant woman presents with three or all four of signs (i), (ii), (iii), and (iv). 
     
     
         8 . The method of  claim 3 , comprising collecting the vaginal fluid sample from the pregnant woman with a collection device. 
     
     
         9 . The method of  claim 8 , wherein the collection device is a flocked swab. 
     
     
         10 . The method of  claim 9 , wherein the flocked swab provides a 1:4 dilution of any PAMG-1 present in the vaginal fluid sample. 
     
     
         11 . The method of  claim 8 , comprising contacting the collection device with a solvent to release the collected vaginal fluid sample. 
     
     
         12 . The method of  claim 3 , comprising collecting the vaginal fluid sample over a time period of about 30 seconds. 
     
     
         13 . The method of  claim 11 , comprising contacting the collection device with the solvent for about 30 seconds after collecting the vaginal fluid sample. 
     
     
         14 . The method of  claim 3 , wherein the vaginal fluid sample is contacted with the at least two PAMG-1-specific monoclonal antibodies for 5 minutes. 
     
     
         15 .- 20 . (canceled) 
     
     
         21 . The method of  claim 3 , wherein the at least two PAMG-1 specific monoclonal antibodies are used in a lateral flow device. 
     
     
         22 . The method of  claim 21 , wherein the lateral flow device comprises a pad region and a test region. 
     
     
         23 . The method of  claim 22 , wherein the pad region of the test device comprises one of the at least two PAMG-1 specific monoclonal antibodies and the test region comprises the other of the two, and wherein the PAMG-1 specific monoclonal antibody in the pad region is mobilizable and the PAMG-1 specific monoclonal antibody in the test region is immobilized. 
     
     
         24 . The method of  claim 23 , wherein the test region of the test device further comprises a control region. 
     
     
         25 . The method of  claim 3 , wherein one or more of the at least two PAMG-1-specific monoclonal antibodies is an antibody selected from the group consisting of M271, produced by hybridoma N271, deposited with the Russian National Collection of Industrial Microorganisms (VKPM) Depository and assigned accession number VKPM-93; and M52, produced by hybridoma N52, deposited with the VKPM and assigned accession number VKPM-92; and M42, produced by hybridoma N42, deposited with the VKPM and assigned accession number VKPM-94. 
     
     
         26 . The method of  claim 25 , where the mobilizable antibody in the pad region is M271, produced by hybridoma N271, deposited with the Russian National Collection of Industrial Microorganisms (VKPM) Depository and assigned accession number VKPM-93, and the immobilized antibody in the test region is M52, produced by hybridoma N52, deposited with the VKPM and assigned accession number VKPM-92. 
     
     
         27 .- 44 . (canceled) 
     
     
         45 . The method of  claim 9 , wherein the flocked swab provides a dilution of any PAMG-1 present in the vaginal fluid sample in a range of 1:1 to 1:10.